Frontiers in Immunology (Sep 2023)
Commentary: Targeting chemoattractant chemokine (C–C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders
Abstract
No abstracts available.Keywords